ERBB2 and breast cancer: In in vivo model, intraperitoneal (IP) administration of NAX014 was able (a) to delay the development of mammary tumors, (b) to reduce the tumor volume and tumor vessel density and (c) to increase tumor cell senescence in HER-2/neu transgenic mice [11].